Inhibition of CD36 and FABP4 significantly reduces the proliferation, migration, invasiveness, and tumorsphere-forming capacity of breast cancer cells, which is associated with reduced tumorigenicity in a xenograft mouse model (Gyamfi et al. 2021). Here, CD36 is linked to breast cancer.